General Information of Drug (ID: DMDPJ8M)

Drug Name
BMY-20844 Drug Info
Synonyms
Bmy-20844; 124886-01-7; UNII-ALR3F45M10; CHEMBL88583; ALR3F45M10; 1,3-Dihydro-7,8-dimethyl-2H-imidazo(4,5-b)quinolin-2-one; 1,3-dihydro-7,8-dimethyl-2H-imidazo[4,5-b]quinolin-2-one; 2H-Imidazo[4,5-b]quinolin-2-one,1,3-dihydro-7,8-dimethyl-; 2H-Imidazo[4,5-b]quinolin-2-one, 1,3-dihydro-7,8-dimethyl-; 2H-Imidazo(4,5-b)quinolin-2-one, 1,3-dihydro-7,8-dimethyl-; AC1NUPC3; ACMC-1C2JD; SCHEMBL2457579; 7,8-dimethyl-1,3-dihydroimidazo[4,5-b]quinolin-2-one; CTK4B4100; DTXSID40154516; ODCKPUDNMNCWMR-UHFFFAOYSA-N; BDBM50000925
Cross-matching ID
PubChem CID
5487281
CAS Number
CAS 124886-01-7
TTD Drug ID
DMDPJ8M

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cilostazol DMZMSCT Intermittent claudication BD40.00 Approved [2]
Aminophylline DML2NIB Bronchial asthma CA23 Approved [3]
Anagrelide DMSQ8MD Thrombocythemia 3B63 Approved [4]
Enoximone DMQVZJD Congestive heart failure BD10 Approved [5]
VESNARINONE DMBKX3C Cardiac failure BD10-BD13 Approved [6]
BEMORADAN DMUL6GY Heart failure BD10-BD13 Phase 2 [7]
CI-930 DMADPQX N. A. N. A. Discontinued in Phase 2 [8]
EMD-53998 DMVS8IE Cardiovascular disease BA00-BE2Z Discontinued in Phase 1 [7]
IMAZODAN DMWTFO3 N. A. N. A. Terminated [9]
LAS-31180 DMW2K1L Heart failure BD10-BD13 Terminated [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Phosphodiesterase 3A (PDE3A) TT06AWU PDE3A_HUMAN Inhibitor [1]

References

1 Inhibitors of blood platelet cAMP phosphodiesterase. 3. 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives with enhanced aqueous solubility. J Med Chem. 1992 Jul 10;35(14):2688-96.
2 A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45.
3 Topical fat reduction from the waist. Diabetes Obes Metab. 2007 May;9(3):300-3.
4 Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45.
5 Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin... J Med Chem. 1987 Feb;30(2):303-18.
6 Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors. Bioorg Med Chem. 2010 Jan 15;18(2):855-62.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
8 Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazi... J Med Chem. 1989 Feb;32(2):342-50.
9 3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase. J Med Chem. 1992 Feb 21;35(4):620-8.
10 Pharmacological profile of LAS 31180, a new inotropic/vasodilator quinolone derivative. Arzneimittelforschung. 2000 Nov;50(11):980-6.